Buh bye
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
56,047 shares traded
If I was a retail short, right now? Wow, I would be freaking out.
Very obvious what is going on now...
That's the problem with recursion. You eat enough resources and the system can slow way down. They must have traversed all the graphs or are very nearly close to doing so.
Better dump the stack and try something else.
Funny how folks don't realize that all of this stuff is running in memory somewhere, managed by a bot.
This is EXACTLY why material events change the game dramatically.
The bots are running out of traversals in their graphs...
Trading, loss-profits, and algorithms, OH MY ...
Summary: "The algorithm made me do it!"
It is important to begin by reflecting on some core traits that every algorithmic trading strategy should have. The strategy should be market prudent in that it is fundamentally sound from a market and economic standpoint. Also, the mathematical model used in developing the strategy should be based on sound statistical methods.
Next, it is crucial to determine what information your robot is aiming to capture. In order to have an automated strategy, your robot needs to be able to capture identifiable, persistent market inefficiencies. Algorithmic trading strategies follow a rigid set of rules that take advantage of market behavior and thus, the occurrence of a one-time market inefficiency is not enough to build a strategy around. Further, if the cause of the market inefficiency is unidentifiable, then there will be no way to know if the success or failure of the strategy was due to chance or not.
With the above in mind there are a number of strategy types to inform the design of your algorithmic trading robot. These include strategies that take advantage of
(i) macroeconomic news (e.g. non-farm payroll or interest rate changes) (ii) fundamental analysis (e.g. using revenue data or earnings release notes)
(iii) statistical analysis (e.g. correlation or cointegration)
(iv) technical analysis (e.g. moving averages)
(v) the market microstructure (e.g. arbitrage or trade infrastructure) (vi) any combination of the above.
What about the IP and bio-metric test tubes? The value-loss ratio inverse principle also impacted the valuation substantially. I think DOC may or not may have had an inferred actionable response to the scenario outlined above.
Seems it's plausible that the valuation could been destroyed instead of marginally destroyed.
Yes, this would be event 1, a precursor to Event 2: EMA submission. Hopefully this will come to fruition before 2017 is over.
Post EU partnership and/or EMA submission, that would be well above fair value. Post AA EU and FDA approval, that would be the high-end of value. Unfortunately, per your incredible insight, the company's value is destroyed thanks to DOC, along with the bio-metric test tubes.
Thank you for sharing your transcendent insights, vision, and knowledge.
Look, I'll make it very clear.
1. There are a few events that will either transpire or not within the next several months. Months, not years, not even 1/2 year. Months.
Event 1: EU partner - may or may not be a prereq for EMA submission;
Event 2: EMA submission, Q4
When either or both of the events transpire, the shorts will be finished. Now, as for short interest. Who cares? It's a bunch of algorithms running on a computer somewhere, managing funds based upon blah, blah, blah metrics.
That all gets blown-up when material news lands.
It will be irrelevant soon enough. Do you know what time it is? It's almost "go" time.
I dunno. With DOC destroying the company's value, including all of the superfluous, bio-metric test tubes (run about $2500 a pop), I am very concerned. I also suspect that DOC may have ignored initial offers to sell the company between $10 and $15 per share, so he was let go. The price is now $6 and change. Look what DOC did - are we sure he is still not involved?
Fbg, care to comment?
The sky is falling, it's almost over. I've got my finger on the sell button, but...
There you are! Where have you been? I have sooooooo many questions! I'm thinking of liquidating now before the shorts take it down to $2.25, but now that DOC is gone, maybe the depreciation of value will stop. I'm just very concerned since DOC destroyed the company's value.
FOUR POINT TWO BILLION DOLLARS or $105 pps
After some further DD, I agree with your insight, although I've also learned that is directly tied to DOC losing 40% of shareholder value. So there is an inverse relationship that should be evaluated. I don't understand all of the details, but if you want further understanding reach out to Fbg. He really brings some insight with respect to DOC and the erosion of shareholder value, especially how it relates to short selling.
Good luck!
Excellent point!
Actually, I'm starting think the value is actually an inverse number, probably about -$2 or -$2.5 per share. Given that I hold ~32000. shares, I actually owe wall Street about 70 grand.
Hoping for the best. I should have listened to Fbg.
I think 7.50 is asking a lot. Dan destroying shareholder value is abuse. In fact, it's possible that he also destroyed the labs and existing constructs - maybe that's what's going on. It's so quiet at Advaxis, it makes me wonder.
And Fbg is so intelligent to see through this grand scheme that has fooled everyone but him.
Really amazing!
It's all over. Better pack it in. With Dan completely destroying the value of all of the company's constructs, there is almost no hope. Right now shareholders should be happy if an acquisition occurs near 12pps, which is a 100% premium from today's price - 100% is a great ROI considering how Dan has destroyed the value of the company with his swindling and self-serving ways.
All the talk of $15/share or higher is completely ridiculous. Dan has left the value of the constructs as nearly worthless. IR should have listened to me 6 months ago when I told them to shift gears with leadership. Unfortunately it's too late.
Oh well, I'll get my $12 on a buyout and make around 10% - better than losing money.
RAOFLMAF!
Exactly. Preaching to the choir...
Yes, I get that. What I am saying is that it's "POR". Infer whatever you want, but until there is a PR on a material event, we know nothing.
I will say one thing that is definitely different, which "may" indicate something, again I'm purely speculating though. If you've been noticing the flavor and context of discussions lately, it's telling a different story in terms of what might be concerning from the short-sellers viewpoint.
If true, this is a very good sign.
"If the retail base banded together, they could completely ruin the stock
just the same as an institution could"
This is pure fantasy. Wow. Who do you think has the biggest say?
Wow. Just, wow.
*****Use some common sense before you speculate*****
Here is what we know:
1. EMA submission is on track for Q4 (likely will include an EU partner)
2. Beyond submission it is highly likely that Advaxis will achieve AA for both EU and FDA in 2018
So, take the above in context and envision what the pps might be beyond approval for both EU and FDA. It certainly won't be single-digits and it certainly won't be below the all-time high. Now, the BOD is thinking, hmmm, we see the next 12 months or so and it looks promising. So they project what the company is worth beyond EU and FDA approvals, along with the potential value of multiple constructs. A year or so is nothing in terms of market time.
Now we come to talk around an early BO. Given the above, there is NO WAY the BOD would accept anything remotely close to a value that does not exceed or represents a compelling enough number to meet expectations beyond EU and FDA approval.
Do the math from there.
Go for it. Are you expecting something different? What is IR going to tell you? Material information that is not ready to be disclosed?
Until the company says otherwise, the POR is as follows:
1. Move forward with EMA submission in Q4
2. Communicate material events as appropriate and required by SEC
Outside of this context, all discussion, inference, and speculation is complete and utter donkey dung. Period. End of story. Done.
So, what's next? Wait. We only have a few months until Q4 is over. Something will be communicated within this time frame.
I've contacted the company and they have replied. Don't make a mountain out of a mole hill.
As an FYI to the board:
First, I'm 99% certain that there IS NO any early buy out in the queue. Basically, this is not the POR. It's not rocket science NOR nothing that is not public information. Read the tea leaves.
Second, per POR, Advaxis is moving forward with and on track to complete EMA submission in Q4 of this year. End of story.
Until Advaxis PR's something to the contrary, it's business as usual. You can infer the silence as one of two ways:
1. There are top-secret negotiations going on for a buy out. This is pure speculation, FUD in many cases, and more or less fluffy BS.
2. Advaxis is working hard to get EMA submission ready, as well as identifying an EU partner. This is POR and the most plausible explanation behind what is going on.
Obviously we'll here something within the next several months. Everything else is complete and utter donkey dung.
Note: "POR" - Plan of Record
I keep seeing this number: 4.2 billion
Hey Tinman,
Remember how you were complaining about the price decline and I asserted that ADXS would close up 3% by weeks end?
Well, then, there it is.
Absurd. Completely and total nonsense.
Posted this earlier, "I told you so"...
[
Not only is the assertion wrong, it's completely and totally short sighted - pun intended.
Price is declining? Since when?
Let's see the commentary when this closes green and up 3% by Friday.
]
ADXS above $30 before the year is over.
(Caveat)
EU partner
EMA submission
Have some vision folks; have some vision. Some of you do, but many are in a "negative Nelly" mindset.
GLTAL!
Additionally, fully expect an "immunotherapy" bull rush to occur within the next 2-5 years. If Advaxis could hold on for that, and not sell early, look out above. Word is just starting to buzz around the game-changing potential of immunotherapy and Advaxis has the goods. Just wait until they get their first set of approvals.
It's going to be insane!
No buyout near term, not in the cards
Still on track for scenario where Advaxis lands EU partner, completes EMA submission (Q4), and gains AA for both EU and FDA in 2018.
Buyout will follow, in the many, many billions...
Same here.
Anybody get an email from IR this am?
" they are not familiar with this tech"
GLORIOUS!
This will simply add to the irrational exuberance on the pps when they DO become familiar
Hmmm, looks like it might be just over a week away before...